<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-95004</identifier>
<setSpec>0213-2885</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Urinary tumor markers for bladder cancer</dc:title>
<dc:description xml:lang="en">Over the last years, the non-invasive diagnostic tests, ImmunoCyt /uCyt+, BTA TRAK, BTA stat, NMP22, NMP22 BladderChek and UroVysion, for the diagnosis of bladder carcinomas have been approved. Nonetheless, these new markers have failed to achieve high enough sensitivity and specificity to replace cystoscopy. Globally they have shown higher sensitivity than urine cytology with a median sensitivity and specificity of 64-80% and 71-95% respectively, and median positive and negative predictive values of 49-84% and 79to 95%. The BTA TRAK, BTA stat, NMP22 and NMP22 BladderChek test have the limitation of a high false positive rate in the context of litbiasis, urinary infection or haematuria and do to its low specificity, the use of BTA TRAK, BTA stat, NMP22 and NMP22 BladderChek without first ruling out the presence of a benign or malignant genitourinary disease beside bladder cancer is not recommended. Only the UroVysion test reaches 80% sensitibity and 94% specificity (AU)</dc:description>
<dc:creator>Rodríguez Faba, O</dc:creator>
<dc:creator>Palou, J</dc:creator>
<dc:creator>Villavicencio, H</dc:creator>
<dc:creator>Cosentino, M</dc:creator>
<dc:creator>Gausa, L</dc:creator>
<dc:creator>Gómez, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En los últimos años se han aprobado las pruebas de marcadores tumorales no invasivos para el diagnóstico del carcinoma vesical ImmunoCyt/uCyt+, BTA TRAK, BTA STAT, NMP22, NMP22 BladderChek y UroVysion, sin embargo, ninguno de estos nuevos marcadores ha demostrado una sensibilidad y especificidad de manera simultánea lo suficientemente elevadas que permita sustituir la cistoscopia. Globalmente han demostrado mayor sensibilidad que la citología de orina, con una sensibilidad y especificidad medias del 64,80% y del 71-95% respectivamente, y valores predictivos positivo y negativo medios del 49-84% y del 79-95%. Las pruebas BTA TRAK, BTA stat, NMP22 y NMP22 BladderChek están limitadas por el elevado número de falsos positivos en casos de litiasis, infección urinaria o hematuria y debido a su baja especificidad, no se recomienda el uso de BTA TRAK, BTA stat, NMP22 Y NMP22 BladderChek sin descartar primero la presencia de una enfermedad genitouriana benigna o maligna aparte del cáncer de vejiga. Solamente UroViysion alcanza un 80% de sensibilidad y un 94% de especificidad (AU)</dc:description>
<dc:source>Actas Fund. Puigvert;29(2): 54-60, abr. 2010. tab</dc:source>
<dc:identifier>ibc-95004</dc:identifier>
<dc:title xml:lang="es">Marcadores tumorales urinarios para el cáncer vesical</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d24373^s22002</dc:subject>
<dc:subject>^d14952</dc:subject>
<dc:subject>^d7802^s22002</dc:subject>
<dc:subject>^d30775^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d1774^s22016</dc:subject>
<dc:subject>^d6566^s22016</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d29310</dc:subject>
<dc:subject>^d37519^s22002</dc:subject>
<dc:type>article</dc:type>
<dc:date>201004</dc:date>
</metadata>
</record>
</ibecs-document>
